Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: To quantify the overall contribution of mutations in the currently known amyotrophic lateral sclerosis (ALS) genes in a large cohort of sporadic patients and to make genotype–phenotype correlations.
Methods: Screening for SOD1, TARDBP, FUS, ANG, ATXN2, OPTN, and C9ORF72 was carried out in 480 consecutive patients with sporadic ALS (SALS) and in 48 familial ALS (FALS) index patients admitted to a single Italian referral center.
Results: Mutations were detected in 53 patients, with a cumulative frequency of 11. Seven of them were novel. The highest frequencies of positive cases were obtained in TARDBP (2.7%), C9ORF72 (2.5%), and SOD1 (2.1%). The overall group of mutated patients was indistinguishable from that without mutations as no significant differences were observed with regard to age and site of onset, frequency of clinical phenotypes, and survival. However, by separately evaluating genotype–phenotype correlation in single genes, clinical differences were observed among different genes. Duration of disease was significantly shorter in patients harboring the C9ORF72 expansion and longer in the SOD1 group. A high frequency of predominant upper motor neuron phenotype was observed among patients with TARDBP mutations. Two patients, 1 with C9ORF72 and 1 with SOD1 mutation, had concurrent ANG mutations. Mutations were detected in 43.7% of patients with FALS.
Conclusions: A considerable proportion of patients with SALS harbored mutations in major ALS genes. This result has relevant implications in clinical practice, namely in genetic counseling. The detection of double mutations in 2 patients raises the hypothesis that multiple mutations model may explain genetic architecture of SALS. Neurology® 2012;79:66–72
GLOSSARY
- ALS=
- amyotrophic lateral sclerosis;
- CI=
- confidence interval;
- FALS=
- familial ALS;
- FTD=
- frontotemporal dementia;
- JALS=
- juvenile ALS;
- LMN=
- lower motor neuron;
- SALS=
- sporadic ALS;
- SCA2=
- spinocerebellar ataxia type 2;
- UMN-D=
- upper motor neuron dominant
Footnotes
Study funding: Supported in part by I.CO.M.M. onlus and FIGC (Federazione Italiana Giuoco Calcio).
Supplemental data at www.neurology.org
- Received December 19, 2011.
- Accepted February 23, 2012.
- Copyright © 2012 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disordersSerena Lattante, Stéphanie Millecamps, Giovanni Stevanin et al.Neurology, August 06, 2014 -
Article
The multistep hypothesis of ALS revisitedThe role of genetic mutationsAdriano Chiò, Letizia Mazzini, Sandra D'Alfonso et al.Neurology, July 25, 2018 -
Article
TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansionsYue Yang, Glenda M. Halliday, Matthew C. Kiernan et al.Neurology, October 16, 2019 -
Articles
Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementiaJ. Yan, H.-X. Deng, N. Siddique et al.Neurology, July 28, 2010